Tissue Management Articles & Analysis
11 news found
Today, MicroPort® is focused in covering ten major areas, including Cardiovascular Intervention & Structural Heart Diseases, Electrophysiology & Cardiac Rhythm Management, Orthopedics & Soft Tissue Repair, Endovascular & Peripheral Vascular Diseases, Neurovascular Intervention & Neurosciences, Life Sciences (Endocrine ...
ByRobocath
(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in March. 42nd Annual Cowen Health Care Conference: Profound is ...
Today, MicroPort is focused in covering ten major areas, including cardiovascular intervention & structural heart diseases, electrophysiology & cardiac rhythm management, orthopedics & soft tissue repair, endovascular & peripheral vascular diseases, neurovascular intervention & neurosciences, life sciences (endocrine ...
ByRobocath
(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in A.G.P.’s Virtual MedTech Summer Conference on Thursday, July 29, 2021. ...
(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management ...
(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management ...
The development of tissue engineering and the manufacture of implantable biological tissues represent major socio-economic challenges. ...
ByPoietis
“Launching this next generation device marks a major milestone for our company,” said Ben Chlebina, General Manager, Tissue Genesis. “We are now focusing on expanding the Icellator X into our clinical programs across the United States, as well as launching of our clinical and commercial efforts ...
Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue. ...
“Based on our ongoing studies, tissue-integrated sensor technology has the potential to enable wearables to live up to the promise of personalized medicine, revolutionizing the management of health in wellness and ...
This device can improve patient outcomes and add value in the management of tissue repair,“ said Human Life CORD President Masamitsu Harata. ...